New combo therapy shows promise for myeloma relapse after transplant
NCT ID NCT03413800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusions) to boost the body's ability to fight the cancer. The goal was to improve disease control and delay progression, while monitoring side effects like graft-versus-host disease. Ten adults aged 18-65 participated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montreal, Quebec, H1T2M4, Canada